[144] Surgery Partners, Inc. SEC Filing
Surgery Partners, Inc. (SGRY) Form 144 shows an insider notice for the proposed sale of 25,000 shares of common stock to be executed through UBS Financial Services on 09/05/2025 with an aggregate market value listed at $563,700. The filing states those 25,000 shares were acquired the same day, 09/05/2025, as equity compensation from Surgery Partners, Inc., and the payment/transfer is described as an equity option exercise. The filing also lists multiple recent open-market sales by the same individual, Wayne DeVeydt, during August and early September 2025, including transactions of 100,000; 25,000; 11,865; and several 25,000-share sales with disclosed gross proceeds for each trade. The notice includes the standard insider attestation that no undisclosed material adverse information is known.
Surgery Partners, Inc. (SGRY) — Il modulo Form 144 segnala che un insider ha intenzione di vendere 25.000 azioni ordinarie tramite UBS Financial Services il 05/09/2025, con un valore complessivo indicato di $563.700. La dichiarazione precisa che le 25.000 azioni sono state acquisite lo stesso giorno, 05/09/2025, come compenso azionario da Surgery Partners, Inc., e l’operazione è descritta come un esercizio di opzione azionaria. Il documento elenca inoltre diverse vendite recenti sul mercato aperto effettuate dallo stesso soggetto, Wayne DeVeydt, in agosto e all’inizio di settembre 2025 (inclusi lotti di 100.000; 25.000; 11.865 e varie vendite da 25.000 azioni), con i proventi lordi di ciascuna transazione dichiarati. La comunicazione riporta l’attestazione standard secondo cui non esistono informazioni materiali avverse non divulgate.
Surgery Partners, Inc. (SGRY) — El Formulario 144 muestra que un insider ha notificado la venta propuesta de 25.000 acciones ordinarias a ejecutarse a través de UBS Financial Services el 05/09/2025, con un valor de mercado agregado declarado de $563.700. La presentación indica que esas 25.000 acciones se adquirieron el mismo día, 05/09/2025, como compensación en acciones de Surgery Partners, Inc., y la transferencia se describe como un ejercicio de opción sobre acciones. También se listan varias ventas recientes en el mercado abierto por la misma persona, Wayne DeVeydt, durante agosto y principios de septiembre de 2025, incluyendo transacciones de 100.000; 25.000; 11.865; y varias ventas de 25.000 acciones, con los ingresos brutos divulgados para cada operación. La notificación incluye la declaración estándar del insider de que no conoce información material adversa no divulgada.
Surgery Partners, Inc. (SGRY) — Form 144 서류에 따르면 임원은 2025년 9월 5일 UBS Financial Services를 통해 보통주 25,000주를 매도할 예정이라고 통지했으며, 총 시가 가치는 $563,700로 기재되어 있습니다. 제출 문서에는 해당 25,000주가 2025년 9월 5일 당일 Surgery Partners, Inc.로부터의 주식 보상으로 취득되었고, 지급/이전이 주식 옵션 행사로 설명되어 있다고 나옵니다. 또한 같은 개인인 Wayne DeVeydt가 2025년 8월과 9월 초에 공개 시장에서 최근에 실시한 여러 매도(100,000주; 25,000주; 11,865주 및 여러 차례의 25,000주 매도 포함)와 각 거래별 공시된 총수익이 열거되어 있습니다. 통지에는 공개되지 않은 중대한 불리한 정보가 없음을 확인하는 표준 내부자 진술도 포함되어 있습니다.
Surgery Partners, Inc. (SGRY) — Le formulaire 144 indique qu’un initié a l’intention de vendre 25 000 actions ordinaires via UBS Financial Services le 05/09/2025, pour une valeur marchande totale déclarée de 563 700 $. Le dépôt précise que ces 25 000 actions ont été acquises le même jour, le 05/09/2025, en tant que rémunération en actions de Surgery Partners, Inc., et que le paiement/transfert est décrit comme un exercice d’option sur actions. Le document énumère également plusieurs ventes récentes en marché ouvert par la même personne, Wayne DeVeydt, en août et début septembre 2025, incluant des transactions de 100 000 ; 25 000 ; 11 865 ; et plusieurs ventes de 25 000 actions, avec les produits bruts divulgués pour chaque opération. L’avis comporte l’attestation standard de l’initié selon laquelle il ne connaît aucune information défavorable matérielle non divulguée.
Surgery Partners, Inc. (SGRY) — Das Formular 144 weist darauf hin, dass ein Insider beabsichtigt, am 05.09.2025 über UBS Financial Services 25.000 Stammaktien zu veräußern; der aggregierte Marktwert wird mit $563.700 angegeben. Die Einreichung besagt, dass diese 25.000 Aktien am selben Tag, dem 05.09.2025, als Aktienvergütung von Surgery Partners, Inc. erworben wurden und die Zahlung/Übertragung als Ausübung einer Aktienoption beschrieben wird. Ferner listet die Meldung mehrere jüngste Verkäufe am Markt durch dieselbe Person, Wayne DeVeydt, im August und Anfang September 2025 auf, darunter Transaktionen über 100.000; 25.000; 11.865 sowie mehrere Verkäufe zu je 25.000 Aktien, mit angegebenen Bruttoerlösen für jede Transaktion. Die Mitteilung enthält die übliche Insiderbestätigung, dass keine nicht offengelegten wesentlichen negativen Informationen bekannt sind.
- Form 144 filed publicly providing transparency on planned insider sale
- Broker and exact sale details (UBS, date, shares, aggregate market value) are specified
- Acquisition source disclosed as equity compensation and payment method as equity option exercise
- Multiple recent open-market sales by the same individual in the past three months are reported, which may be viewed negatively by some investors
- Insider selling concentration over a short period could increase share supply pressure
Insights
TL;DR Insider has scheduled a 25,000-share sale after exercising options; multiple recent sales by the same person are disclosed.
The filing documents a routine Rule 144 notice for sale of common shares that were immediately acquired via equity option exercise on the same date as the proposed sale. The use of UBS as broker and clear per-trade gross proceeds for prior sales enhances transparency. From a market-impact perspective, recent concentrated sales by one insider can increase supply pressure in the short term, but the filing itself provides procedural compliance rather than operational insight into the company.
TL;DR Disclosure is procedurally complete; multiple insider transactions warrant attention but do not alone indicate wrongdoing.
The Form 144 includes required information about acquisition source (equity compensation) and payment method (option exercise), which supports compliance with Rule 144. The repeated sales by the same individual over a short window are material to governance observers because they may reflect personal liquidity events. The filing includes the attestation regarding lack of undisclosed material adverse information, consistent with regulatory expectations.
Surgery Partners, Inc. (SGRY) — Il modulo Form 144 segnala che un insider ha intenzione di vendere 25.000 azioni ordinarie tramite UBS Financial Services il 05/09/2025, con un valore complessivo indicato di $563.700. La dichiarazione precisa che le 25.000 azioni sono state acquisite lo stesso giorno, 05/09/2025, come compenso azionario da Surgery Partners, Inc., e l’operazione è descritta come un esercizio di opzione azionaria. Il documento elenca inoltre diverse vendite recenti sul mercato aperto effettuate dallo stesso soggetto, Wayne DeVeydt, in agosto e all’inizio di settembre 2025 (inclusi lotti di 100.000; 25.000; 11.865 e varie vendite da 25.000 azioni), con i proventi lordi di ciascuna transazione dichiarati. La comunicazione riporta l’attestazione standard secondo cui non esistono informazioni materiali avverse non divulgate.
Surgery Partners, Inc. (SGRY) — El Formulario 144 muestra que un insider ha notificado la venta propuesta de 25.000 acciones ordinarias a ejecutarse a través de UBS Financial Services el 05/09/2025, con un valor de mercado agregado declarado de $563.700. La presentación indica que esas 25.000 acciones se adquirieron el mismo día, 05/09/2025, como compensación en acciones de Surgery Partners, Inc., y la transferencia se describe como un ejercicio de opción sobre acciones. También se listan varias ventas recientes en el mercado abierto por la misma persona, Wayne DeVeydt, durante agosto y principios de septiembre de 2025, incluyendo transacciones de 100.000; 25.000; 11.865; y varias ventas de 25.000 acciones, con los ingresos brutos divulgados para cada operación. La notificación incluye la declaración estándar del insider de que no conoce información material adversa no divulgada.
Surgery Partners, Inc. (SGRY) — Form 144 서류에 따르면 임원은 2025년 9월 5일 UBS Financial Services를 통해 보통주 25,000주를 매도할 예정이라고 통지했으며, 총 시가 가치는 $563,700로 기재되어 있습니다. 제출 문서에는 해당 25,000주가 2025년 9월 5일 당일 Surgery Partners, Inc.로부터의 주식 보상으로 취득되었고, 지급/이전이 주식 옵션 행사로 설명되어 있다고 나옵니다. 또한 같은 개인인 Wayne DeVeydt가 2025년 8월과 9월 초에 공개 시장에서 최근에 실시한 여러 매도(100,000주; 25,000주; 11,865주 및 여러 차례의 25,000주 매도 포함)와 각 거래별 공시된 총수익이 열거되어 있습니다. 통지에는 공개되지 않은 중대한 불리한 정보가 없음을 확인하는 표준 내부자 진술도 포함되어 있습니다.
Surgery Partners, Inc. (SGRY) — Le formulaire 144 indique qu’un initié a l’intention de vendre 25 000 actions ordinaires via UBS Financial Services le 05/09/2025, pour une valeur marchande totale déclarée de 563 700 $. Le dépôt précise que ces 25 000 actions ont été acquises le même jour, le 05/09/2025, en tant que rémunération en actions de Surgery Partners, Inc., et que le paiement/transfert est décrit comme un exercice d’option sur actions. Le document énumère également plusieurs ventes récentes en marché ouvert par la même personne, Wayne DeVeydt, en août et début septembre 2025, incluant des transactions de 100 000 ; 25 000 ; 11 865 ; et plusieurs ventes de 25 000 actions, avec les produits bruts divulgués pour chaque opération. L’avis comporte l’attestation standard de l’initié selon laquelle il ne connaît aucune information défavorable matérielle non divulguée.
Surgery Partners, Inc. (SGRY) — Das Formular 144 weist darauf hin, dass ein Insider beabsichtigt, am 05.09.2025 über UBS Financial Services 25.000 Stammaktien zu veräußern; der aggregierte Marktwert wird mit $563.700 angegeben. Die Einreichung besagt, dass diese 25.000 Aktien am selben Tag, dem 05.09.2025, als Aktienvergütung von Surgery Partners, Inc. erworben wurden und die Zahlung/Übertragung als Ausübung einer Aktienoption beschrieben wird. Ferner listet die Meldung mehrere jüngste Verkäufe am Markt durch dieselbe Person, Wayne DeVeydt, im August und Anfang September 2025 auf, darunter Transaktionen über 100.000; 25.000; 11.865 sowie mehrere Verkäufe zu je 25.000 Aktien, mit angegebenen Bruttoerlösen für jede Transaktion. Die Mitteilung enthält die übliche Insiderbestätigung, dass keine nicht offengelegten wesentlichen negativen Informationen bekannt sind.
FAQ
What does the Form 144 for SGRY report?
Who is the individual associated with the sales?
Were the shares acquired from the company or purchased in the market?
Does the Form 144 list prior sales by the insider?
Is there any statement about undisclosed material information?
